HPV vaccination in HIV: immunogenic, and time-critical

Design

systematic review and random-effects meta-analysis with logit transformation, six databases searched 2006 to June 2026, GRADE assessment

Population

25 studies of prophylactic HPV vaccination in people living with HIV; 12 in the quantitative analysis, 1,493 participants for HPV16

Primary outcome

pooled type-specific seroconversion rate

Effect

HPV16 97.8% (94.9-99.1), HPV18 94.2% (86.1-97.7), HPV6 97.0%, HPV11 97.1%; HPV16 seroconversion 98.5% at CD4 above 350 versus 71.1% at 200 or below

People living with HIV carry a disproportionate burden of HPV-related disease, and the question has never been whether to vaccinate but how well the vaccine works when immunity is impaired. This meta-analysis searched six databases from 2006 to June 2026, including 25 studies in the review and 12 in the pooled analysis, with 1,493 participants contributing HPV16 data.

Seroconversion was high across the board: HPV16 97.8% (95% CI 94.9-99.1), HPV18 94.2% (86.1-97.7), HPV6 97.0% and HPV11 97.1%. All three vaccine generations performed similarly, and no vaccine-related serious adverse events were reported. Two doses of the nonavalent vaccine were non-inferior to three in virologically suppressed women in the Papillon randomised trial.

The finding to act on is the modifier. HPV16 seroconversion was 98.5% in those with a CD4 count above 350 but 71.1% in those at 200 or below. That converts a general recommendation into a scheduling one: vaccinate early, and where a patient presents with advanced immunosuppression, establish antiretroviral therapy and immune recovery before or alongside vaccination rather than vaccinating once and considering it done. In India, where HPV vaccine is now in the national programme for girls and where HIV care and cervical screening often sit in different services, the practical gap is usually referral rather than supply.

• Vaccinate early in the HIV course — response falls sharply below a CD4 count of 200
• Where CD4 is low at presentation, prioritise antiretroviral therapy and revisit vaccination after recovery
• Two doses of nonavalent vaccine were non-inferior to three in virologically suppressed women
• Seroconversion is an immune marker, not a demonstration of prevented cancer — continue screening regardless
• Link HIV clinics to cervical screening actively; vaccination does not replace it

The statistics, in plain English

Heterogeneity was very high for most estimates (I-squared 89.6% for HPV16, 95.8% for HPV18), meaning the studies disagreed substantially and the pooled percentage describes no single population well. GRADE certainty was moderate for HPV16, HPV6 and HPV11 and low for HPV18, so the HPV18 figure should be held most loosely. The CD4 comparison comes from a single trial within the review rather than a pooled analysis, so the 98.5% against 71.1% contrast is a finding from one study, not a synthesised estimate. Seroconversion is a surrogate: no study here measured cancer or persistent infection.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.